Format

Send to

Choose Destination
Cell Immunol. 2018 Mar;325:48-55. doi: 10.1016/j.cellimm.2018.02.002. Epub 2018 Feb 7.

CD103+CD8+ T lymphocytes in non-small cell lung cancer are phenotypically and functionally primed to respond to PD-1 blockade.

Author information

1
Department of Thoracic Surgery, Tong Ji Medical School, Huazhong University of Science and Technology, China; Laboratory of Thoracic Surgery, Tong Ji Hospital, Tong Ji Medical School, Huazhong University of Science and Technology, China.
2
Laboratory of Cell Engineering, Tong Ji Medical School, Huazhong University of Science and Technology, China.
3
Department of Thoracic Surgery, Tong Ji Medical School, Huazhong University of Science and Technology, China; Laboratory of Thoracic Surgery, Tong Ji Hospital, Tong Ji Medical School, Huazhong University of Science and Technology, China. Electronic address: fuxn2006@aliyun.com.
4
Department of Thoracic Surgery, Tong Ji Medical School, Huazhong University of Science and Technology, China; Laboratory of Thoracic Surgery, Tong Ji Hospital, Tong Ji Medical School, Huazhong University of Science and Technology, China. Electronic address: lqli@tjh.tjmu.edu.cn.

Abstract

CD103+CD8+ tumor infiltrating lymphocytes (TILs) have been linked to prolonged survival in various types of cancer including non-small cell lung cancer (NSCLC). However, the factors associated with the retention of CD103+CD8+ TILs in lung cancer tissues remain largely unknown. Additionally, the contribution of CD103+CD8+ TILs to effective PD-1 based immunotherapy has not been fully elucidated. In this study, we identified that the expression levels of E-cadherin and TGF-β were significantly correlated with the distribution and the density of CD103+ TILs in lung cancer tumor tissues. Unexpectedly, we observed that CD103+CD8+ TILs that expressed higher levels of PD-1 co-express Ki-67. Moreover, CD103+CD8+ TILs expressed an increased level of T-bet compared to their counterparts, indicating these cells may be better armed for immunotherapy. Lastly, PD-1 pathway blockade led to a significantly increased production of IFN-γ by CD103+CD8+ TILs, suggesting CD103+CD8+ TILs could serve as a predictive biomarker for PD-1 based immunotherapy.

KEYWORDS:

CD103; IFN-γ; Non-small cell lung cancer; PD-1; T-box transcription factors

PMID:
29448979
DOI:
10.1016/j.cellimm.2018.02.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center